Cannabigerol, commonly known as CBG, is a remarkable and lesser-known cannabinoid found in cannabis plants. While often overshadowed by its more famous counterparts like THC and CBD, CBG is gaining increased attention within the rapidly growing field of cannabinoid research. It is sometimes referred to as the “mother of all cannabinoids” because it is the precursor to other cannabinoids. This unique compound has been a subject of scientific exploration, and its potential health benefits are becoming more evident. In this article, we will delve into the world of CBG, exploring its origins, effects, and the emerging scientific knowledge surrounding its therapeutic potential. Whether you’re an experienced cannabis enthusiast or just curious about the world of cannabinoids, this introduction to CBG will provide valuable insights into this intriguing compound.

What is CBG?

Cannabigerol, or CBG, is a non-psychoactive cannabinoid that is one of the many chemical compounds found within the cannabis plant. It’s often referred to as the “stem cell” or “mother” of all cannabinoids because it serves as the precursor for the development of other major cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD). CBG is produced in the early stages of the cannabis plant’s growth, and as the plant matures, it undergoes enzymatic changes that convert CBG into other cannabinoids, making it a relatively rare compound in mature cannabis plants.

Research into CBG is still in its infancy, but initial studies suggest that this cannabinoid has a diverse range of potential health benefits. It interacts with the endocannabinoid system (ECS), a complex network of receptors and neurotransmitters that play a crucial role in maintaining homeostasis within the body. Some of its potential effects include anti-inflammatory, pain-relieving, and neuroprotective properties, making it a subject of interest for researchers looking to harness its therapeutic potential. As our understanding of CBG continues to evolve, it holds promise as a valuable addition to the growing field of medicinal cannabinoids, offering unique benefits beyond its more well-known counterparts like CBD and THC.

References:

1. Taha E. M., et al. (2021). Cannabigerol: A Review of CBG and its Effects on Inflammatory Biomarkers and Other Related Conditions. Phytotherapy Research, 35(3), 1216-1225.
2. Cascio M. G., Gauson L. A., Stevenson L. A., et al. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159(1), 129-141.

The Rising Popularity of CBG

In recent years, CBG has garnered increasing attention within the cannabis industry and the broader field of health and wellness. This growing popularity can be attributed to several factors, with one of the most prominent being the extensive research on the potential therapeutic benefits of CBG. As studies on the compound continue to emerge, it’s becoming clear that CBG offers a range of health-related advantages, such as anti-inflammatory, analgesic, and neuroprotective effects. These findings have led to an upsurge in demand for CBG-infused products, as consumers seek alternatives to traditional pharmaceuticals and explore the potential of this non-psychoactive cannabinoid.

Furthermore, the wellness industry’s continuous expansion has opened doors for the incorporation of CBG into various products, including tinctures, oils, capsules, and topicals. This widespread availability has made it more accessible to individuals who are interested in exploring the potential benefits of CBG. Additionally, as more consumers become health-conscious and look for natural remedies, the appeal of CBG, derived from the cannabis plant, aligns with the growing preference for plant-based alternatives. This has contributed to the surge in CBG’s popularity, as individuals search for holistic solutions to manage various health conditions.

Despite its newfound fame, CBG remains relatively less understood compared to other cannabinoids like CBD and THC. However, the increased interest and the ongoing research on CBG have propelled it into the spotlight and are leading to greater insights into its potential uses. This shift in popularity reflects the evolving attitudes toward cannabis and its constituents, demonstrating a growing acceptance of cannabinoids as a viable and natural approach to health and wellness.

References

1. Oláh, A., Markovics, A., Szabó-Papp, J., et al. (2016). Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Experimental Dermatology, 25(9), 701-707.
2. Andre, C. M., Hausman, J. F., & Guerriero, G. (2016). Cannabis sativa: The Plant of the Thousand and One Molecules. Frontiers in Plant Science, 7, 19.

The Science Behind CBG

To comprehend the intricate properties and potential therapeutic benefits of Cannabigerol (CBG), it is essential to explore the underlying science that governs this fascinating cannabinoid. CBG, often referred to as the “mother of all cannabinoids,” serves as the precursor to many other well-known compounds, such as THC and CBD, within the cannabis plant. Its unique chemical structure and interactions with the endocannabinoid system (ECS) give rise to a wide range of effects and therapeutic potential. This introductory exploration of the science behind CBG will unravel the compound’s distinct properties, revealing its intricate role in modulating physiological functions and its promise as a valuable addition to the realm of cannabinoid-based therapies.

CBG v CBD: What’s the difference?

Cannabigerol (CBG) and Cannabidiol (CBD) are two prominent cannabinoids found in the cannabis plant, each with its distinct characteristics and potential therapeutic applications. One of the key distinctions between these cannabinoids lies in their precursor role within the cannabis plant. CBG, often referred to as the “mother cannabinoid,” is the chemical precursor to both CBD and THC. In contrast, CBD is a derivative of cannabigerolic acid (CBGA), a precursor to CBG. This fundamental difference in their biosynthetic pathways gives rise to their distinct chemical structures and effects.

While CBD is known for its non-psychoactive nature, CBG, too, is non-psychoactive, meaning it does not induce the euphoric “high” associated with THC. However, CBG’s effects and potential applications differ from those of CBD. Studies suggest that CBG may exhibit stronger binding affinities to certain cannabinoid receptors, such as the CB1 and CB2 receptors, which are key components of the endocannabinoid system (ECS). This variance in receptor affinity may contribute to CBG’s unique potential to alleviate pain, reduce inflammation, and support the nervous system, setting it apart from CBD in terms of its specific therapeutic applications.

The unique characteristics of CBG and CBD continue to pique the interest of researchers and healthcare professionals, as they explore the potential of these cannabinoids in addressing a wide range of health conditions. While both offer therapeutic promise, understanding the differences in their chemical makeup, receptor interactions, and potential effects is crucial for tailoring cannabinoid-based treatments to specific needs and conditions.

References

1. Pamplona, F. A., da Silva, L. R., & Coan, A. C. (2018). Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Frontiers in Neurology, 9, 759.
2. Brierley, D. I., Samuels, J., Duncan, M., et al. (2016). Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats. Psychopharmacology, 233(19-20), 3603-3613.

How is CBG produced in hemp plants?

Cannabigerol (CBG) is biosynthesised within hemp plants through a series of intricate enzymatic processes. CBG begins as cannabigerolic acid (CBGA), often referred to as the “mother” or “stem cell” cannabinoid, and is formed within the trichomes, the resin glands on the surface of the hemp plant. Over time, as the hemp plant matures, enzymes within the plant catalyse the conversion of CBGA into other major cannabinoids like THC, CBD, and CBC. This process typically involves the action of specific enzymes, such as THCA synthase and CBDA synthase, which guide the transformation of CBGA into these other cannabinoids. Consequently, as the hemp plant ages, the concentration of CBG diminishes, making it a relatively minor constituent in fully matured hemp plants. Researchers are actively exploring methods to maximise CBG production, whether through selective breeding or genetic modification, to create hemp strains with higher CBG content for potential therapeutic applications.

References:

1. Marks, M. D., Tian, L., Wenger, J. P., et al. (2009). Identification of candidate genes affecting Δ9-tetrahydrocannabinol biosynthesis in Cannabis sativa. Journal of Experimental Botany, 60(13), 3715-3726.
2. Sirikantaramas, S., Taura, F., Tanaka, Y., et al. (2005). Tetrahydrocannabinolic acid synthase, the enzyme controlling marijuana psychoactivity, is secreted into the storage cavity of the glandular trichomes. The Plant Cell, 17(8), 2277-2291.

How CBG Interacts with the Endocannabinoid System

Cannabigerol (CBG) interacts with the endocannabinoid system (ECS), a complex regulatory network of receptors and neurotransmitters that plays a pivotal role in maintaining homeostasis within the body. CBG’s interaction with the ECS is a subject of active research, and while our understanding is evolving, some insights have emerged. CBG’s mode of action within the ECS includes its influence on the CB1 and CB2 receptors. CBG has a relatively low affinity for both of these receptors, but its impact may be more pronounced when the ECS is imbalanced or under certain conditions.

CBG is believed to act as a modulator rather than a direct agonist of the CB1 and CB2 receptors, meaning it can influence the activity of these receptors indirectly. This modulation can affect the way these receptors interact with other cannabinoids, such as THC, and endocannabinoids produced by the body. Additionally, CBG may exert its effects by interacting with other non-cannabinoid receptors and pathways, contributing to its diverse potential therapeutic applications. As research continues, a clearer understanding of how CBG interacts with the ECS will likely provide valuable insights into its mechanisms of action and the full scope of its therapeutic benefits.

While there is still much to learn about CBG’s precise role within the ECS, initial studies suggest that it may help regulate various physiological processes, such as pain perception, inflammation, mood, and immune response. These findings make CBG a compound of significant interest to researchers and healthcare professionals seeking to harness its potential for addressing a wide range of health conditions.

References:

1. Cascio, M. G., Gauson, L. A., Stevenson, L. A., et al. (2010). Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. British Journal of Pharmacology, 159(1), 129-141.
2. Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344-1364.

Potential Health Benefits of CBG

CBG for Pain Relief

Cannabigerol (CBG) is increasingly being investigated for its potential in providing pain relief, offering an alternative to conventional pain management approaches. Emerging research suggests that CBG interacts with the endocannabinoid system (ECS) to modulate pain signaling. By influencing receptors and neurotransmitters within the ECS, CBG may play a role in alleviating pain perception. While more extensive clinical trials are needed to establish its efficacy definitively, early studies have shown that CBG exhibits anti-inflammatory properties and is capable of reducing pain-related symptoms in various conditions, making it an exciting prospect for those seeking natural pain relief options.

Furthermore, CBG’s pain-relieving potential may extend beyond its interaction with the ECS. Studies have indicated that CBG can influence other non-cannabinoid receptors, such as alpha-2 adrenergic and 5HT1A receptors, which are involved in pain modulation. These interactions could contribute to CBG’s ability to mitigate pain and discomfort. Whether used alone or in combination with other cannabinoids, CBG’s multifaceted approach to pain management is an area of research that holds great promise, offering potential relief for individuals dealing with chronic pain conditions.

As research into CBG continues to unfold, it is essential to recognize that individual responses to CBG for pain relief may vary, and its efficacy could depend on the specific pain condition and other factors. However, as part of the broader exploration of cannabinoids for pain management, CBG’s potential is a noteworthy development that could provide an alternative for those seeking natural, non-addictive solutions to alleviate pain.

References:

1. Taha, E. M., et al. (2021). Cannabigerol: A Review of CBG and its Effects on Inflammatory Biomarkers and Other Related Conditions. Phytotherapy Research, 35(3), 1216-1225.
2. Russo, E. B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, 4(1), 245-259.

CBG and Anxiety

Cannabigerol (CBG) has emerged as a subject of interest in the field of anxiety management due to its interactions with the endocannabinoid system (ECS). Although research on CBG’s effects on anxiety is in its infancy, early studies suggest that this cannabinoid may have potential in this area. CBG is believed to influence the ECS by interacting with the CB1 and CB2 receptors, which play crucial roles in regulating mood and anxiety. While CBG’s affinity for these receptors is relatively low compared to THC or CBD, its modulatory effect on these receptors may contribute to its potential as an anxiolytic agent. This modulation can influence the release of neurotransmitters, such as serotonin, which are associated with mood regulation, potentially providing relief for anxiety-related symptoms.

Moreover, CBG’s potential as an anti-inflammatory and neuroprotective agent adds to its appeal as an anxiety-reducing compound. Inflammation and neuroinflammation have been linked to mood disorders, including anxiety. CBG’s anti-inflammatory properties may help mitigate inflammatory responses in the brain, thereby indirectly impacting anxiety levels. As further research delves into CBG’s specific mechanisms of action and its effects on anxiety, it offers a promising avenue for individuals searching for alternative, natural solutions to address this common mental health concern.

It is important to note that while CBG’s early findings are promising, more comprehensive clinical studies are necessary to confirm its effectiveness in managing anxiety. Additionally, individual responses to CBG may vary, and its potential benefits in anxiety management may depend on factors such as dosage, the presence of other cannabinoids, and the specific form of CBG used.

References:

1. Shannon, S., Opila-Lehman, J. (2016). Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Permanente Journal, 20(4), 108-111.
2. Jadoon, K. A., Ratcliffe, S. H., Barrett, D. A., et al. (2016). Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care, 39(10), 1777-1786.

CBG for Inflammation

Cannabigerol (CBG) is emerging as a promising candidate in the realm of inflammation management, reflecting the expanding interest in cannabinoids for their anti-inflammatory properties. CBG interacts with the endocannabinoid system (ECS), playing a role in regulating immune responses and inflammation within the body. CBG’s mechanism of action is multifaceted, as it influences the CB1 and CB2 receptors, which are key components of the ECS. By modulating these receptors, CBG may help regulate the immune response, potentially reducing inflammation. This modulation can impact the release of pro-inflammatory cytokines, ultimately contributing to the management of inflammatory conditions.

Recent studies have provided insights into CBG’s potential as a powerful anti-inflammatory agent. Research findings indicate that CBG can inhibit the production of nitric oxide, a molecule that plays a significant role in the inflammatory process. Additionally, CBG may possess anti-oxidative properties that protect cells from oxidative stress and damage, which can exacerbate inflammatory conditions. As the body of evidence supporting the anti-inflammatory effects of CBG continues to grow, it offers hope for those seeking natural remedies for various inflammatory disorders, such as arthritis, colitis, and neuroinflammatory conditions.

Although CBG’s potential for managing inflammation is promising, further research, including clinical trials, is essential to fully elucidate its efficacy and safety for specific inflammatory conditions. The exploration of CBG’s unique properties, combined with its low psychoactivity, positions it as an intriguing compound within the growing field of cannabinoid-based therapies for inflammation.

References:

1. Oláh, A., Markovics, A., Szabó-Papp, J., et al. (2016). Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrhoeic skin and acne treatment. Experimental Dermatology, 25(9), 701-707.
2. Smeriglio, A., Giofre, S. V., Galati, E. M., Monforte, M. T., & Cicero, N. (2018). Inhibition of Aldose Reductase Activity by Cannabis sativa chemotypes extracts with high content of cannabidiol or cannabigerol. Fitoterapia, 127, 101-108.

Neuroprotective Properties of CBG

Cannabigerol (CBG) is increasingly garnering attention for its potential neuroprotective properties, offering a promising avenue in the search for therapies against neurodegenerative conditions and other neurological disorders. CBG interacts with the endocannabinoid system (ECS), which plays a vital role in regulating various neurological functions. Emerging research suggests that CBG can influence the ECS to mitigate neuroinflammation and oxidative stress, two significant contributors to neurodegenerative diseases such as Alzheimer’s and Parkinson’s. In experimental studies, CBG has demonstrated its ability to protect neurons from damage, promote neurogenesis (the formation of new nerve cells), and improve overall brain health.

Furthermore, CBG’s anti-inflammatory and antioxidant properties contribute to its neuroprotective potential. By reducing neuroinflammation and oxidative stress, CBG can help safeguard brain cells from damage and degradation. These characteristics make CBG an appealing candidate for future therapeutic applications in the field of neurology. While clinical research is still in its early stages, the promise of CBG’s neuroprotective properties holds great potential for those searching for alternative treatments for neurodegenerative disorders and other neurological conditions.

In addition to its potential for neurodegenerative diseases, CBG’s neuroprotective properties have sparked interest in its role in mitigating the effects of brain injuries and other neurological traumas. Experimental evidence suggests that CBG may assist in protecting the brain from damage caused by injuries and traumatic events. As research continues to evolve, the scope of CBG’s neuroprotective benefits and its practical applications within the realm of neurological health are expected to become clearer.

References:

1. Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., & Muñoz, E. (2015). Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1), 185-199.
2. Giacoppo, S., Gugliandolo, A., Trubiani, O., et al. (2019). Cannabinoid CB2 receptors are involved in the protection of RAW264.7 macrophages against the oxidative stress: An in vitro study. European Journal of Histochemistry, 63(2), 3211.

CBG and Glaucoma

Cannabigerol (CBG) has attracted attention for its potential in managing glaucoma, a condition characterized by elevated intraocular pressure (IOP) that can lead to optic nerve damage and vision loss. While most research has centered on THC’s ability to reduce IOP, early studies suggest that CBG may also have a role to play. CBG interacts with the endocannabinoid system (ECS), which includes receptors in the eye, making it a plausible candidate for glaucoma treatment. CBG is believed to influence the flow of aqueous humor, the clear fluid that maintains IOP. By modulating this flow, CBG may help to reduce IOP, potentially providing relief to individuals with glaucoma.

Moreover, CBG’s potential anti-inflammatory and antioxidant properties could contribute to its efficacy in managing glaucoma. Inflammation and oxidative stress are factors that can exacerbate the progression of glaucoma. Early research findings indicate that CBG may help mitigate these contributors, thereby offering further support for its role in glaucoma treatment. While additional studies are needed to confirm its effectiveness, the potential of CBG for glaucoma patients is an encouraging development in the exploration of natural treatments for this condition.

It’s important to note that while CBG’s potential for managing glaucoma is promising, its effects on intraocular pressure may be relatively short-lived compared to some other conventional medications. Therefore, further research, including clinical trials, is essential to determine the optimal usage and efficacy of CBG for glaucoma management.

References:

1. ElSohly, M. A., Slade, D. (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sciences, 78(5), 539-548.
2. Miller, S., Daily, L., Leishman, E., Bradshaw, H., Straiker, A. (2018). Delta-Tetrahydrocannabivarin and cannabigerol, but not delta-9-tetrahydrocannabinol, produce antinociception in the mouse formalin test. Neuropharmacology, 143, 55-63.

CBG for Skin Conditions

Cannabigerol (CBG) is increasingly being explored for its potential benefits in skincare and the management of various skin conditions. One of CBG’s promising attributes is its anti-inflammatory properties, which are valuable for conditions like eczema, psoriasis, and acne, where inflammation plays a significant role. CBG’s interactions with the endocannabinoid system (ECS) can help regulate immune responses and reduce skin inflammation. Furthermore, CBG’s ability to inhibit the production of nitric oxide, which contributes to skin inflammation, makes it a promising candidate for soothing irritated skin and potentially alleviating the discomfort associated with various skin conditions.

CBG also exhibits antioxidant properties, which are essential for promoting skin health. Oxidative stress can lead to premature aging and skin damage, and CBG may counteract these effects by neutralising harmful free radicals. By protecting skin cells from oxidative damage, CBG can support overall skin health and potentially mitigate skin conditions. While the research on CBG for skincare is still in its early stages, its potential as a natural remedy for various skin conditions is a subject of growing interest.

References:

1. Oláh, A., Tóth, B. I., Borbíró, I., et al. (2014). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. Journal of Clinical Investigation, 124(9), 3713-3724.
2. Lombardo, E., Arlotta, C., Mancini, F., & Raffaelli, M. (2020). Neuroprotective and Anti-Inflammatory Properties of Cannabidiol and Cannabigerol in Multiple Sclerosis and in Amyotrophic Lateral Sclerosis. CNS & Neurological Disorders-Drug Targets, 19(9), 693-700.

Antioxidant and Anti-Inflammatory Effects of CBG

Cannabigerol (CBG) is increasingly recognized for its potential as a potent antioxidant and anti-inflammatory agent. CBG’s antioxidant properties play a crucial role in neutralizing harmful free radicals and reducing oxidative stress. By safeguarding cells and tissues against damage caused by free radicals, CBG supports overall health and may contribute to its potential benefits in addressing various inflammatory conditions. Emerging research indicates that CBG can help counteract oxidative stress, making it a promising candidate for conditions where inflammation and oxidative damage play a significant role, such as neurodegenerative disorders and skin conditions.

Moreover, CBG’s anti-inflammatory properties are of significant interest in the field of health and wellness. Inflammation is a common factor in many health conditions, and CBG’s ability to modulate the endocannabinoid system (ECS) can help regulate immune responses and reduce inflammation. This anti-inflammatory action has led to investigations into CBG’s potential for conditions like inflammatory bowel disease, arthritis, and even neuroinflammation. While research on CBG’s antioxidant and anti-inflammatory effects is still in its early stages, these properties make it a promising candidate in the development of natural remedies for various health conditions.

References:

1. Valdeolivas, S., Navarrete, C., Cantarero, I., Bellido, M. L., & Muñoz, E. (2015). Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 12(1), 185-199.
2. Oláh, A., Tóth, B. I., Borbíró, I., et al. (2014). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. Journal of Clinical Investigation, 124(9), 3713-3724.

Conclusion

The Growing Interest in CBG

The growing interest in CBG (Cannabigerol) signifies a transformative shift in the way we approach health and wellness. This lesser-known cannabinoid has emerged from the shadows of THC and CBD, captivating the attention of both the scientific community and individuals seeking natural remedies. As research expands and real-life experiences continue to validate its potential, CBG is poised to play a pivotal role in the future of healthcare. Its versatility, non-intoxicating nature, and preliminary findings in pain relief, anxiety management, skin health, and other areas have positioned it as a promising option for those looking to address a broad spectrum of health concerns. While much research is still needed to unlock the full extent of CBG’s therapeutic potential, its journey from obscurity to prominence is a testament to the dynamic evolution of our understanding and utilisation of cannabinoids in the pursuit of improved health and well-being.

CBG’s Potential Role in Future Health and Wellness

CBG’s rapid rise in popularity and expanding body of research suggest that it may play a vital role in the future of health and wellness. As our understanding of this cannabinoid deepens and more clinical trials are conducted, we can anticipate the development of innovative CBG-based treatments and products that offer solutions for a range of health concerns. From pain management and anxiety reduction to skin health and potential applications in areas like cancer research, CBG is poised to provide a versatile and non-intoxicating alternative for individuals seeking natural remedies. As it continues to gain recognition and acceptance, CBG may become an integral part of the evolving landscape of healthcare, offering new and effective tools to support holistic well-being.

Key Takeaways

This discussion on CBG (Cannabigerol) highlights several key takeaways. First and foremost, CBG is emerging as a promising and versatile cannabinoid with a wide range of potential health benefits. Its non-intoxicating nature and preliminary research findings in areas like pain relief, anxiety management, and skin health make it an attractive option for individuals seeking natural remedies. Real-life stories and personal experiences further reinforce the cannabinoid’s potential, echoing the early research that suggests CBG’s diverse applications.

Second, ongoing research and clinical trials are essential in unlocking CBG’s full therapeutic potential. While anecdotal evidence and preliminary findings are promising, rigorous scientific investigations are needed to confirm the safety, efficacy, and optimal dosages of CBG for specific medical conditions. As CBG continues to gain recognition and acceptance, its place in healthcare and wellness may become more firmly established, offering a new dimension to holistic health and medical treatments. Overall, CBG’s journey from relative obscurity to a prominent position in health and wellness is indicative of the evolving landscape of cannabinoid utilisation and its role in addressing a wide array of health concerns.